Moscow Seed Fund and RVC Biofund invest in the technology of cancer diagnostic at early stages

Moscow Seed Fund, together with RVC Biofund, have invested 16 million rubles in the "RTM Diagnostics" project.

The investments will be directed primarily at ensuring a broad technology patenting in Russia, Europe and the United States, bringing to the market a new version of diagnostic equipment and the expansion of the screening platform line in the areas such as urology, neurology, traumatology, rehabilitation and treatment monitoring.

The RTM Diagnostics Company specializes in the development and commercialization of deep radiometry technology based on the measurement of natural electromagnetic radiation of human tissues in the microwave range of wavelengths and infrared wavelengths, which helps to non-invasively detect temperature anomalies at a depth of several centimeters. This method makes it possible to diagnose the presence of malignant tumors at early stages, while the technique is absolutely harmless and can be used as a rapid method of diagnosis.

Today, the radiometry method is actively used in the diagnosis of breast diseases, where 85-92% of sensitivity and 70-75% of specificity are achieved. The use of safe diagnostic method in young, pregnant and lactating women is currently one of the most fundamental in diagnosing cancer at an early stage, which greatly improves the accuracy of diagnosis and prescribed treatment. Surely, this method can become one of the priorities at the time of diagnosis together with other diagnostic methods.

The radiometry method is indispensable in the areas such as mammology because screening by means of this technology makes it possible not only to see the problem early, but to prescribe effective treatment. Currently, the control of patients' treatment is the most important task of the medical sphere, because women's health depends on it in general. For many female patients, the method that is able to not only detect the disease, but also helps to retain the breast is very important and we are ready to develop this technology, giving patients the right to life and the doctors the right to a professional and quality approach to treatment, said Alexander Romanov, MD, professor, corresponding member of the Academy of Medical Sciences, Honored Doctor of the Russian Federation, Honored Scientist of Russia.

Currently, healthcare more than ever needs a technology that will provide a clear understanding of a revealed pathology in humans. The only thing that many current diagnostic standards can do is just to state the fact of a disease. Moreover, this applies to every field - from pediatrics to gynecology. Indispensable is the method that can give an idea about the disease at an early stage, giving the doctor a chance to prevent a more serious illness. Our goal is to find the application of radiometry technology in addition to breast care, because this method has the potential in different areas. Our task is to actively support the work on implementing this method of diagnosis to the grass roots and to find technological solutions for various applications, improving the diagnostic process, said Sergey Vesnin, the founder of RTM Diagnostics and the author of the project.

The investment funds attracted together with Moscow Seed Fund will help the company to solve its tasks by expanding the product line and the bringing to the market a new generation of diagnostic tools, said the director of the RVC Biofund Egor Beketov.